×

RNS Number : 1420O

N4 Pharma PLC

28 May 2020

 

28 May 2020

 

N4 Pharma plc

("N4 Pharma", the "Company" or the "Group")

 

Covid-19 Project Update

 

Further to the Company's announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on the progress of its Covid-19 proof of concept work for Nuvec®.

As previously announced, the Company appointed Evotec International Gmbh ("Evotec") to undertake the Nuvec® proof of concept work. The Company can confirm that the first phase of the project has been carried out, within the expected timeframe, and that the plasmid DNA has been successfully amplified to produce sufficient material for the rest of the project and has been tested to confirm it matches the required specification. Evotec has also used this batch of the plasmid DNA to express the Covid-19 spike protein to be used as a positive control for the studies. Evotec will now move to the second phase of the work and start the in-vitro testing of Nuvec® as planned, during the first week of June 2020. This phase is expected to last approximately ten weeks.

The third phase of the in-vivo protein expression testing will be to undertake an initial pre in-vivo study to demonstrate expression of the spike protein in target cells in a murine target. Following the recent fundraise, announced on 13 May 2020, the Company is now also exploring ways in which it can bring forward the start of certain areas of this third phase to run alongside the in-vitro work.

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: +44(0)203 328 5656
Turner Pope Investments (TPI) Ltd Andrew Thacker	Tel: +44(0)20 3657 0050
Scott PR Georgia Smith	Tel: +44(0)1477 539 539

 

About N4 Pharma

 

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDGZGZKGNRGGZZ

Close

×

RNS Number : 9614N

Plant Health Care PLC

27 May 2020

 

 

RNS

 

27 May 2020

 

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Update on PHC279 2019 Field Trials

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update on its completed 2019 field trials of the PREtec peptide PHC279 for the control of plant diseases in corn, wheat and lettuce crops.

 

Highlights:

 

US Corn

–  PHC 279 increased corn yields by 9-15% when applied as a foliar spray, creating potential grower value of $54 – $82 per acre at current average prices.

–  PHC279 significantly improved the control of two key corn diseases by as much as 50%, even under heavy disease pressure.

Spring wheat

–  PHC279 increased yield by as much as 17% when added to the standard disease control program,   which is worth $86 per acre at current prices.

Lettuce

–  PHC279 increased yield by as much as 22% compared to fungicides alone.

–  PHC279 also improved disease control as much as 31% following foliar application.

 

In the US, 91m acres of corn were planted in 2019. Severe southern rust disease can routinely reduce corn yields as much as 25 bushels per acre. At current prices, this would equate to lost revenue for the farmer of $79 per acre. In historical epidemics of southern corn leaf blight, yields were reduced by 20 to 25 percent nationwide, resulting in an estimated $1 billion loss in harvest.  In the Company's trials, when PHC279 was applied together with a leading chemical fungicide, it significantly improved control of both diseases compared to the fungicide treatment alone, and yields were increased by as much as 26 bushels per acre depending on application timing. Even a more modest benefit of 5-10 bushels per acre is likely to provide an attractive return on investment in the potential range of 5:1 to 8:1 for farmers who apply PHC279 to their fields.

 

In the UK, when PHC279 was applied to spring wheat seeds prior to planting, followed by adding it to the standard spray fungicide program, yield was increased by as much as 17% in fields with Septoria tritici blotch, the major disease of wheat in the UK. At current prices, this yield benefit would be worth $86 per acre to the farmer.

 

Lettuce drop disease is a major pathogen affecting US lettuce cultivation. In a series of US field trials inoculated with Sclerotinia , the causative agent of lettuce drop disease, PHC279 treated plants yielded as much as 22% more than plants treated only with the standard chemical fungicide program. With an acre of lettuce worth more than $10,000 in the US in 2018, even a modest increase in lettuce yield will likely justify the cost of applying PHC279.

 

Plant Health Care's PREtec peptides stimulate the plant to defend itself. Derived from natural proteins, this is a novel, environmentally friendly approach to protecting crops and increasing yields, compatible with mainstream agricultural practice.   PHC279 may allow farmers to reduce applications of toxic fungicides or to achieve better control of disease.

 

Gary L. Cloud, Ph.D., a research agronomist and owner of GLC Consulting, Inc. participated in the testing of PHC279 in corn this season, and offered the following, "There was heavy disease pressure and PHC279 provided visible improvement in disease control and higher yield compared to the standard fungicide when applied early in the growing season.  That is somewhat amazing due to the time that elapsed between application and harvest. I believe PHC279 will be a valuable tool for corn growers struggling to control disease in their fields."

 

Chris Richards, CEO of Plant Health Care, said "We are extremely encouraged with the performance of PHC279 in multiple key crops. Building on our recent success with PHC279 for the control of Asian soybean rust in Brazil, it is clear PHC279 will have important benefits for farmers in many crops. The registration of our first PREtec peptide is progressing in the US and Brazil and the scale-up of manufacturing has started.  We are excited about the potential for products based on our PREtec peptides, which are targeting markets with an initial opportunity of $5 billion.  We aim to launch the first peptides as soon as regulatory permits have been obtained, to offer these valuable new tools to growers in the US and other countries."

 

 

For further information, please contact:

Plant Health Care plc

Chris Richards, CEO  Tel: +1 919 926 1600

Arden Partners plc – Nomad & Broker

John Llewellyn-Lloyd / Dan Gee-Summons  Tel: +44 (0) 20 7614 5900

Company website: www.planthealthcare.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDUNAORROUVUAR

Close

×

RNS Number : 8176N

Tracsis PLC

26 May 2020

 

26 May 2020

Tracsis plc

("Tracsis" or the "Group")

Large Rail Contract Wins

 

Tracsis, a leading provider of software, hardware and services for the rail, traffic data and wider transport industries, is pleased to announce that it has been awarded two major rail contracts.

The first award is a further significant contract for the provision of its TRACS Enterprise software product with another major UK rail operator. The contract will be delivered over multiple years and is for several million pounds, which includes the renewal of some existing systems already licenced by the customer, plus significant levels of additional functionality through the TRACS Enterprise suite, including the ATTUne timetabling software that was added to the Group via the acquisition of Bellvedi Limited in April 2019.

The contract will not have a major financial impact in the current financial year ending 31 July 2020 but helps to underpin our confidence for the future, and the product suite that has been in significant development in recent years.

The second win is a major order for the provision of remote condition monitoring technology, plus our associated Centrix software and related support services, to an existing customer. The contract is for several hundred thousand pounds, and will be delivered over the coming months.

The Rail Technology and Services division continues to operate with high activity levels, and continues to pursue a number of other new opportunities across its range of software offerings.

 

Chris Barnes, Chief Executive Officer, commented:

"We are delighted to have secured these major contracts with two major UK rail customers and look forward to delivering these projects in the months to come. The UK rail industry continues to adopt our award winning TRACS Enterprise software and remote condition monitoring technology, both of which can bring significant benefits to the operators, and these latest wins are testament to the strength of our team and quality of our market leading products."

Enquiries:

Tracsis plc                                          Tel: 0845 125 9162

Chris Barnes, CEO

Max Cawthra, CFO

finnCap Ltd          Tel: 020 7220 0500

Christopher Raggett/Charlie Beeson, Corporate Finance

Andrew Burdis, Corporate Broking

 

 

 

Notes to editors: 

· Tracsis plc is a technology company and a leading provider of software and hardware products, data capture and data analytic services for the rail, traffic data and wider transport industries.

· Tracsis' products and services are widely used to increase efficiency, reduce cost and risk and improve operational and asset performance, safety management and decision making capabilities for clients and customers. 

· The Group is split into two principle operating areas built around detailed industry knowledge and expertise:

–  Rail Technology & Services:  Software and technology led business supported by consultancy. Develops remote condition monitoring hardware and safety, productivity improvement, risk management and data acquisition software for rail infrastructure providers and software that solves complex resource, asset optimisation and control problems for Train Operators.

–  Traffic & Data Services: A largely services led business that focuses on data capture, data analytics, data insights and event traffic management within transport and pedestrian rich environments.  The business provides technology and data that underpins large scale intelligent transport system and smart city planning and decision making.

· Tracsis has a blue-chip client base which includes all major UK transport owning Groups.  The business also works extensively with Network Rail, the Department of Transport, TfL, multiple local authorities, major outdoor music and sporting event organisers, and a wide variety of large engineering and infrastructure companies.

· The business drives growth both organically and through acquisition and has made fourteen acquisitions since 2008.

· For more information on Tracsis please visit http://www.tracsis.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTFIFEDELISFII

Close

×

RNS Number : 8337N

Panoply Holdings PLC (The)

26 May 2020

 

26 May 2020

 

The Panoply Holdings PLC

("The Panoply", the "Group", and the "Company")

 

Contract win, trading update and private investor webinar

 

The Panoply (AIM: TPX), a digitally native technology-enabled services company, is pleased to announce that Group business FutureGov has signed a significant digital transformation contract with a large, global philanthropic organisation.

 

This contract, which is worth a total of US$5.2m over 14 months, will see FutureGov supporting the organisation's teams across EU capital cities to focus on and transform local government services in order to deliver better outcomes. Using its extensive experience and expertise in the digital transformation sector, FutureGov will produce bespoke, digitally-enabled community focused services that seek to address current major issues facing communities.

 

This contract is another success for the Group in the public sector, further demonstrating the strength of the Group's offering in this field, the importance of its purpose-driven work and also its ability to continue securing significant new business wins even during this time of heightened uncertainty.

 

Trading update

Coming into the current financial year, the Group had a confirmed backlog deliverable in the year, including annualised recurring revenue, of approximately £15m. The contract with the philanthropic organisation is one of a number of new business wins the Group has signed in the last eight weeks (since 1 April 2020), which comprises a total value of £9.5m, the majority of which will be delivered this financial year.

 

The Group expects to report a strong performance for the first quarter of FY21 with year-on-year organic growth on a like-for-like pro forma basis*. Margins are expected at pre-COVID-19 levels, driven by the volume of new work secured. Alongside this the Group expects continued profitability and strong cash generation.

 

Whilst the uncertainty created by the COVID-19 pandemic means it remains very difficult to predict performance going forward, the Group remains confident in its market offering that spans technology, design and strategy, with around 70% of pro forma revenues now coming from public services.

 

*Q1 FY20 revenue on a pro forma basis, including Ameo and FutureGov, would have been approximately £9.1m. Ameo and FutureGov have been included to show a true like-for-like comparison.

 

Investor webinar

Further to this update, The Panoply's CEO, Neal Gandhi and CFO Oliver Rigby will be hosting a private investor webinar on Tuesday, 2 June 2020 at 14.00. Registration for the webinar is available via the following link: https://bit.ly/TPX_Update

 

Issue of consideration shares

As announced on 28 April 2020, the acquisitions made by the Group to date have traded in line with expectations and so it is anticipated that further consideration in line with previous guidance of approximately £17m will become payable. This consideration will become payable following the release of the Group's FY20 results, expected to be in July 2020, and will result in the issue and allotment of c.21.5m new shares in The Panoply. This represents c.40% of the current issued share capital.

 

Neal Gandhi, CEO of The Panoply commented:

"We always believed that our aim of being purposeful in our approach would deliver great financial returns. This has been proven so far this year with the group winning £9.5m in new work since April 1st, an eight week period that for many has been the most challenging in living memory. I'm immensely grateful to our people who have gone above and beyond in order to deliver what looks set to be a record Q1 with organic growth on a like for like basis.

 

I would particularly like to mention our teams that have been involved in COVID-19 emergency response related projects. They have worked tirelessly to deliver projects in difficult circumstances that have contributed to ensuring those most in need of help have received it."

 

 

Enquiries:

The Panoply Holdings Neal Gandhi (CEO) Oliver Rigby (CFO)	Via Alma PR
Stifel (Nomad and Broker) Fred Walsh Alex Price	+44 (0)207 710 7600
Alma PR (Financial PR) Josh Royston Susie Hudson	[email protected] +44(0)203 405 0206 07780 901979

 

About The Panoply

 

The Panoply is a digitally native technology services company, built to service clients' digital transformation needs. Founded in 2016, with the aim of identifying and acquiring best-of-breed specialist information technology, design and innovation consulting businesses across Europe, the Group collaborates with its clients to deliver the technology outcomes they're looking for at the pace that they expect and demand.

 

More information is available at www.thepanoply.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

TSTAAMLTMTJTBRM

Close

×

RNS Number : 8930L

1PM PLC

05 May 2020

 

5 May 2020

 

 

1pm plc

("1pm", the "Group" or the "Company")

Coronavirus Business Interruption Loan Scheme accreditation

and

COVID-19 update

 

1pm plc (AIM: OPM), the AIM listed independent specialist provider of finance facilities to UK SMEs, is pleased to announce that it has been approved for accreditation as a lending partner under the Government's Coronavirus Business Interruption Loan Scheme ("CBILS"). CBILS is administered by British Business Bank. In addition, the Company provides a further update on the impact of COVID-19 on the Group's business activities.

 

CBILS accreditation

The British Business Bank has approved 1pm Finance (UK) Ltd, a wholly-owned subsidiary of the Company, which trades as Onepm Finance ("Onepm"), for accreditation as a participating lender under CBILS.

 

Since the beginning of the COVID-19 crisis, 1pm has resolved to remain open for new business to support credit-worthy, robust SMEs as well as helping its existing 20,000 customers. Becoming an accredited lender will enable the Group to expand its lending in the form of leases and loans to UK small business customers across the UK impacted by the COVID-19 pandemic with the benefit for the Group of a government-backed guarantee for the loan repayments due from the borrower.

 

The Group is in the process of determining the amount of funding it expects to be able to deploy for CBILS related lending and the Board is confident that becoming an accredited lender, subject to the allocation and availability of suitable funding, will have the potential to make a significant impact on the number of new lending agreements.

 

The CBILS accreditation will provide an additional means for 1pm to deliver support to SMEs, adding to the Group's current lending activities in the form of Asset Finance, through wholesale finance facilities provided by British Business Bank and a range of challenger banks; Loan Finance through the Group's Secured Loan Note programme; and Invoice Finance through a back-to-back facility provided by RBS/NatWest.

 

In addition to the government-backed guarantee, the Government will make a Business Interruption Payment to cover the first 12 months of interest payments due and charges levied. It is anticipated that following a short period of preparation to be undertaken in conjunction with British Business Bank, including staff training and entry into underlying agreements, Onepm will be in a position to commence lending under CBILS during May 2020. Onepm thereafter intends to be an active lender for the duration of the CBILS scheme.

 

James Roberts, Chief Financial Officer, commented:

 

"We are delighted to have been approved to become an accredited partner to the UK Government's lending programme helping us to deliver additional funding to UK small businesses when they need it most. Small businesses are the lifeblood of the UK economy and 1pm is pleased to be able to assist where we can during this critical time."

 

COVID-19 Update

As stated in the Group's COVID-19 update on 26 March 2020, the principles by which the Group is operating are:

· a dedicated focus on the health and safety of the Group's employees and their families

· an uninterrupted seamless service for customer and client transactions

· unwavering support to viable businesses for which finance solutions have been provided

· remaining open for new business to support credit-worthy, robust SMEs

 

The Group is pleased to report that after seven weeks of remote working, operations continue to be effectively and successfully carried out in respect of all four of these principles. The Group has used the Coronavirus Job Retention Scheme and furloughed approximately one-third of its 184-strong workforce.

The highest proportion of furloughed staff are employed in the Group's vehicles and property loans brokerage businesses where trading volumes have reduced significantly. These activities account for less than 10 per cent of the Group's profit before tax, since the majority of the Group's revenues and profits are generated from its lending activities.

Supported by CBILS, lending will continue strongly in certain business sectors, particularly those identified as critical. These include lending to SMEs in the food supply chain (agriculture, transportation and retail); medical, pharmaceutical and healthcare; IT and telephony; waste disposal and industrial cleaning; and certain sub-sectors in manufacturing.

In common with most businesses operating in the non-bank, specialist lending sector, 1pm has seen a number of existing borrowers requesting payment delays, holidays, or similar forbearance as they adjust to substantial losses of revenue. The Group has to date received forbearance requests from approximately 25 per cent of its borrowers, representing approximately 15 per cent of the Group's portfolio by value.

 

As previously announced and consistent with the Company's standard approach, 1pm has dealt with these in-bound requests from borrowers on a case-by-case basis in agreeing to provide appropriate support.

 

1pm will continue to support credit-worthy customers and businesses so that they can resume normal trading at a future date. It is impossible to predict with any accuracy what the coming months will hold for the UK's economy and, therefore, as a responsible finance provider, the Group will continue to be prudent and in so doing will make additional impairment provisions in the current financial year ending on 31 May 2020.

 

The Board confirms that 1pm has a strong financial base to operate from with a robust balance sheet (showing unaudited Net Assets of £56.1m as at 30 November 2019), with operational liquidity, covenant headroom, and committed funding facilities for current lending activities. The Company's lenders continue to be unanimously supportive of the Group.

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

For further information, please contact:
1pm plc
Ian Smith, Chief Executive Officer	07768 394162
James Roberts, Chief Financial Officer	01225 474230
Cenkos (NOMAD)
Max Hartley / Ben Jeynes (Nomad) Julian Morse (Sales)	0207 397 8900
Walbrook PR	0207 933 8780
Paul Vann	07768 807631
	[email protected]

 

About 1pm:

1pm's strategy is to focus on providing or arranging the finance UK SMEs require to fund their businesses and arranging vehicle and property-backed finance for consumers. The multi-product range for SMEs includes asset, vehicle, loan and invoice finance facilities. The Group operates a "hybrid" lending and broking model enabling it to optimize business levels through market and economic cycles.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

TSTKKQBPKBKBAPK

Close

×

RNS Number : 7406L

EVR Holdings PLC

04 May 2020

 

 

EVR Holdings plc

('EVR' or the 'Company')

 

MelodyVR launches 'On stage', a free-to-fan content series 

 

· Starting o n May 5th, the music series will feature global superstars including Julia Michaels, Lewis Capaldi, Panic! At The Disco, Wiz Khalifa and more

 

· Available on smartphones and VR headsets to homes around the world, shows will be made free-to-view, for one night only

 

EVR Holdings plc ​ (AIM:EVRH), the leading creator of virtual reality entertainment content and operator of the MelodyVR platform, is pleased to announce that MelodyVR will be throwing open its virtual doors to relive some of the best live shows and tours. Screening via the MelodyVR app, the On Stage series will be available to music fans around the world for free. 

 

MelodyVR is inviting friends and families to join in together to experience immersive performances from the likes of Panic! At The Disco, Lewis Capaldi, Frank Carter & The Rattlesnakes, Fall Out Boy and Imagine Dragons from home. Further shows will be announced in due course.

 

Launching wit h global R&B singer-songwriter sensation Khalid on May 5th, users can tune in via smartphone or VR headsets to relive the performance from his acclaimed Free Spirit tour. In VR and in stunning 360° on MelodyVR, fans can use the app to switch jump-spots to get the best view, stand on stage with their heroes, and experience all the spine-tingling, heart-lifting power of a live show, without leaving their homes.

 

The launch week schedule of free MelodyVR screenings is:

 

Khalid at The O2 arena	Tues May 5	6pm LA	9pm NYC	2am+1 day LDN
Lewis Capaldi at Fonda Theatre	Wed May 6	11am LA	2pm NYC	7pm LDN
Wiz Khalifa at Roundhouse	Wed May 6	4pm LA	7pm NYC	12am+1 day LDN
Julia Michaels at House of Blues	Thurs May 7	6pm LA	9pm NYC	2am+1 day LDN
Frank Carter & The Rattlesnakes at Alexandra Palace	Fri May 8	11am LA	2pm NYC	7pm LDN
Panic! At The Disco at The O2 arena	Fri May 8	6pm LA	9pm NYC	2am+1 day LDN
Fall Out Boy at Talking Stick Resort Arena	Sat May 9	6pm LA	9pm NYC	2am+1 day LDN
Imagine Dragons at Red Rocks Amphitheatre	Sun May 10	11am LA	2pm NYC	7pm LDN

 

 

 

 

About MelodyVR

 

MelodyVR launched in 2018 with a simple mandate: not to replace the live music experience, but to harness the power of virtual reality to get people closer to the music they love.

 

By using VR technology, the founders realised that they could place fans in the crowd or on stage with their favourite musicians at live events. From epic stadium shows to intimate studio performances, the possibilities are endless: capacity restrictions are eliminated, music lovers can attend otherwise sold-out dates, and the barriers (distance, age, cost, access) that might keep people from experiencing their heroes live are swept away. The result? Artists can reach more fans than ever before, with a level of intimacy which has previously not been possible.

MelodyVR is the only licensed VR music platform and has the world's largest library of exclusive immersive and interactive music experiences from the likes of Post Malone, Lewis Capaldi, Mabel, Wiz Khalifa, Kelly Clarkson, KISS, Niall Horan, Katherine Jenkins, Fall Out Boy, The Chainsmokers and Imagine Dragons.

Available on smartphones and VR headsets, the MelodyVR app can be downloaded at on.melodyvr.com/App

 

For further information please contact:

EVR Holdings plc
Anthony Matchett , Executive Chairman & CEO	[email protected]
Arden Partners plc: Nominated Adviser and Broker Corporate Finance: Ciaran Walsh / Ruari McGirr / Ben Cryer Corporate Broking: Simon Johnson	Tel: +44 (0) 20 7614 5900

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRADGGDUSGGDGGX

Close

×

RNS Number : 7231K

Genedrive PLC

24 April 2020

 

genedrive plc

("genedrive" or the "Company")

 

Distribution agreement for AIHL test

 

 Inspiration Healthcare to distribute genedrive's Antibiotic Induced Hearing Loss test in UK & Ireland

Option to expand agreement to engage Inspiration Healthcare's global neonatal sub-distributor network

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a contract for the distribution of the Company's Antibiotic Induced Hearing Loss test (Genedrive® MT-RNR1) in the UK and Ireland with Inspiration Healthcare Group plc (AIM: IHC) ("Inspiration Healthcare"). The companies also expect to expand the scope of the contract over time to engage Inspiration Healthcare's specialty network of over 50 neonatal focussed sub-distributors around the world.

 

David Budd, Chief Executive Officer of genedrive plc, said: "Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought leading healthcare company with a specialist emphasis on neonatal care. Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together."

 

The Genedrive ® MT-RNR1 test is the world's first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics.   In the UK, 90,000 babies are admitted to NICU units each year, and 80-85% of them receive antibiotics. Genedrive's rapid genetic test can be completed in less than 30 minutes, allowing for correct treatment decision on antibiotics to be made within one hour of admission, as required by the UK's National Institute of Clinical Excellence (NICE).

 

Neil Campbell, Chief Executive Officer of Inspiration Healthcare, commented : "We are delighted to be able to work with genedrive plc with this novel testing device for new born babies that could suffer hearing loss due to antibiotics given to them on admission into neonatal intensive care. Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world."

genedrive plc	+44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	+44 (0)20 7418 8900
James Steel / Oliver Jackson
finnCap Ltd	+44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 or [email protected]
Paul McManus / Anna Dunphy	+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, Antibiotic Induced Hearing Loss, and has tests in development for tuberculosis (mTB) and SARS-CoV-2.

 

 

About Inspiration Healthcare (http://www.inspiration-healthcare.com)

 

Inspiration Healthcare is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

 

Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.

 

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe. In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

AGREAELDAASEEAA

Close

×

RNS Number : 7167K

N4 Pharma PLC

24 April 2020

 

24 April 2020

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

New Nuvec® opportunity and patent filing

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that it has filed a new UK patent application around both Nuvec®'s ability to be used to manufacture viral vectors and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments.

 

Nuvec® has a unique structure that allows the easy loading of DNA plasmids. The manufacture of viral vectors typically requires the use of two or more plasmids. Nuvec® has been shown to be capable of loading multiple plasmids. In recent research conducted by the Company, it has been demonstrated that loading Nuvec® with the three plasmids typically used to produce lentivirus, resulted in an increase in the amount of the desired viral vector produced.  The manufacture of viral vectors is an expensive process, so utilising Nuvec®'s ability to efficiently load and deliver multiple plasmids could greatly reduce the cost involved in this process.

An important use of viral vectors is in ex-vivo gene therapy. In this approach, a patient's cells are taken from their body and more are grown in the laboratory. Whilst still outside the body, these cells are modified by adding the gene of interest into the cells' DNA by using viral vectors that are carrying the gene. These cells, carrying the gene designed to treat the patient, are then re-inserted back into the patient's body. In separate research, the Company has demonstrated that when complexed with a lentivirus carrying a gene of interest, Nuvec® can be used as a reagent to produce cells containing the gene using a fraction of the original lentivirus, thereby suggesting that this process can be made cheaper and more efficient.

The Company is now working with external consultants to identify how best to enter the virus manufacture and ex-vivo gene therapy markets .

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"Whilst investigating the dispersion of Nuvec® to improve its in-vivo consistency, we have been undertaking research on the in-vitro applications of Nuvec® as all our data shows good and consistent loading and in-vitro transfection using Nuvec®.

 

"The global viral vector manufacturing market was valued at $273 million in 2017 and is expected to grow to $816 million by 2023 . Sales of transduction reagents were estimated to be $68m in 2017 and growing to $123m by 2024.

 

"These are significant markets for in-vitro applications of Nuvec® and will allow us to look at additional commercial opportunities whilst we continue to develop our in-vivo data package for licensing Nuvec® as a delivery system for cancer treatments and vaccines. "

 

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: +44(0)203 328 5656
Scott PR Georgia Smith	Tel: +44(0)1477 539 539

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCSESFMDESSEIL

Close

×

Neville Registrars is delighted to welcome ABEO Investments Limited as the newest addition to its list of client companies.

ABEO Investmentsis a newly formed Residential Property Investment Company.

Further information can be found on the Company's website: http://www.abeoinvestments.co.uk/

Close

×

RNS Number : 4692J

DeepMatter Group PLC

14 April 2020

 

14 April 2020

RNS Reach

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter's technology selected by Cancer Research UK Beatson Institute

Cancer Research UK Beatson Institute to trial DigitalGlassware™ within its Drug Discovery Unit to enhance the reproducibility of its chemistry and accelerate drug discovery

 

14 April 2020 – DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry has signed a contract with the Cancer Research UK Beatson Institute and Cancer Research Technology (the commercialisation and development arm of Cancer Research UK) for its DigitalGlassware™ platform. The technology will be installed within the institute's Drug Discovery Unit to enable the accurate and reproducible sharing of its research output with its outsourced chemistry partners located in China. The use of DigitalGlassware™ means the Drug Discovery Unit will be able to share its cutting-edge chemistry across locations, so that work is not needlessly duplicated nor time and money wasted, and ultimately so new discoveries might be made faster. 

 

The DigitalGlassware™ platform will allow the Drug Discovery Unit to accurately and systematically record, code and enter the results of their experiments into a shared data cloud, enabling the sharing of details of their experiments from anywhere and in real-time.

 

A subsequent deployment in China is anticipated to take place later in 2020.

 

Mark Warne, CEO of DeepMatter Group, commented: "We are very proud to be working with Cancer Research UK Beatson Institute, one of Europe's leading cancer research centres, and delighted that through the use of our technology, DeepMatter is able to support them in their life-saving work.

 

"The difficulty in consistently reproducing quality chemistry globally is an issue that continues to plague chemists. DigitalGlasswareTM addresses this problem and we believe it has the potential to transform the industry ."

 

Justin Bower, Joint Head of the Drug Discovery Unit and Head of Chemistry at the Cancer Research UK Beatson Institute, added: "We know that improved reproducibility in our work, particularly when achieved across multiple sites, will lead to enhanced productivity and a faster speed of discovery. DeepMatter's technology is some of the most innovative we have seen to date and we look forward to working with them test its capabilities."

 

For more information, please contact:

DeepMatter Group plc	T: 0141 548 8156
Mark Warne, Chief Executive Officer
C anaccord Genuity Limited (Nominated Advisor and Broker)	T:  020 7523 8000
Bobbie Hilliam / Angelos Vlatakis
Alma PR Caroline Forde / Susie Hudson / Harriet Jackson	T: 020 3405 0205 [email protected]
Cancer Research UK Beatson Institute	T: 0141 330 3953
Head of Chemistry/Joint Head of BDDU, Justin Bower

 

About DeepMatter Group plc  

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors. 

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster. 

 

Visit: www.deepmatter.io and follow @deepmattergroup 

 

Cancer Research UK Beatson Institute

The Cancer Research UK Beatson Institute in Glasgow, directed by Professor Owen Sansom, is one of Europe's leading cancer research centres, supporting cutting-edge work into the molecular mechanisms of cancer development. As well as core support from Cancer Research UK, the Institute also receives income from a number of external grants and industry collaborations. The Beatson has an excellent reputation for fundamental cancer research, including world-class metabolism studies and renowned in vivo modelling of tumour growth and metastasis. Its Drug Discovery Unit, headed by Justin Bower and Heather McKinnon, is central to its mission to apply cancer discovery for patient benefit. www.beatson.gla.ac.uk .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAIJMLTMTABBFM

Close